Cancer upregulated gene 2, a novel oncogene, confers resistance to oncolytic vesicular stomatitis virus through STAT1-OASL2 signaling

Cancer Gene Therapy

Volumn 20, Issue 2, 2013, Pages 125-132

  Malilas, W ^a   Koh, S S ^b   Srisuttee, R ^a   Boonying, W ^a   Cho, I R ^a   Jeong, C S ^c   Johnston, R N ^d   Chung, Y H ^a  

^a Pusan National University   (South Korea)

^b University of Science and Technology (UST)   (South Korea)

^c University of Ulsan   (South Korea)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

CUG2; OASL2; STAT1; virotherapy; VSV

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; MESSENGER RNA; OASL2 PROTEIN; SMALL INTERFERING RNA; STAT1 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOLYSIS; NONHUMAN; ONCOGENE; ONCOGENE CUG2; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VESICULAR STOMATITIS VIRUS; VIRUS RESISTANCE;

2',5'-OLIGOADENYLATE SYNTHETASE; ANIMALS; CELL LINE, TUMOR; COLONIC NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NIH 3T3 CELLS; NUCLEAR PROTEINS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; VESICULAR STOMATITIS; VESICULAR STOMATITIS INDIANA VIRUS;

VESICULAR STOMATITIS VIRUS;

EID: 84874112788     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2012.96     Document Type: Article

References (35)

1. Lee S, Gang J, Jeon SB, Choo SH, Lee B, Kim YG et al. Molecular cloning and functional analysis of a novel oncogene, cancer-upregulated gene 2 (CUG2). Biochem Biophys Res Commun 2007; 360: 633-639.
2. Kim H, Lee M, Lee S, Park B, Koh W, Lee DJ et al. Cancer-upregulated gene 2 (CUG2), a new component of centromere complex, is required for kinetochore function. Mol Cells 2009; 27: 697-701.
3. Park EH, Park EH, Cho IR, Srisuttee R, Min HJ, Oh MJ et al. CUG2, a novel oncogene confers reoviral replication through Ras and p38 signaling pathway. Cancer Gene Ther 2010; 17: 307-314.
4. Rose JK, Whitt MA. Rhabdoviridae: The Viruses and their Replication. In Knipe DM, Howley PM (eds). Field Virology. 4th edn, Lippincott Williams and Wilkins: New York, 2001, 1221-1244.
5. de Mattos C, de Mattos CC, Rupprecht CE. Rhabdoviridae: The Viruses and their Replication. In: Knipe DM, Howley PM (eds). Field Virology. 4th edn, Lippincott Williams and Wilkins: New York, 2001, 1245-1277.
6. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-376.
7. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science 1998; 282: 1332-1334.
8. Varghese S, Rabkin SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 2002; 9: 967-978.
9. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000; 6: 821-825.
10. Fernandez M, Porosnicu M, Markovic D, Barber GN. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol 2002; 76: 895-904.
11. Leveille S, Samuel S, Goulet ML, Hiscott J. Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy. Cancer Gene Ther 2011; 18: 435-443.
12. Li Q, Tainsky MA. Epigenetic silencing of IRF7 and/or IRF5 in lung cancer cells leads to increased sensitivity to oncolytic viruses. PLoS One 2011; 6: e28683.
13. Stephenson KB, Barra NG, Davies E, Ashkar AA, Lichty BD. Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity. Cancer Gene Ther 2012; 19: 238-246.
14. Porosnicu M, Mian A, Barber GN. The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene. Cancer Res 2003; 63: 8366-8376.
15. Hovanessian AG. On the discovery of interferon-inducible, double-stranded RNA activated enzymes: the 20-50 oligoadenylate synthetases and the protein kinase PKR. Cytokine Growth Factor Rev 2007; 18: 351-361.
16. Justesen J, Hartmann R, Kjeldgaard NO. Gene structure and function of the 2'-5'-oligoadenylate synthetase family. Cell Mol Life Sci 2000; 57: 1593-1612.
17. Skaug B, Chen ZJ. Emerging role of ISG15 in antiviral immunity. Cell 2010; 143: 187-190.
18. MacMicking JD. IFN-inducible GTPases and immunity to intracellular pathogens. Trends Immunol 2004; 25: 601-609.
19. Carter CC, Gorbacheva VY, Vestal DJ. Inhibition of VSV and EMCV replication by the interferon-induced GTPase, mGBP-2: differential requirement for wild-type GTP binding domain. Arch Virol 2005; 150: 1213-1220.
20. Liu M, Guo S, Hibbert JM, Jain V, Singh N, Wilson NO et al. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev 2011; 22: 121-130.
21. Liu XY, Chen W, Wei B, Shan YF, Wang C. IFN-induced TPR protein IFIT3 potentiates antiviral signaling by bridging MAVS and TBK1. J Immunol 2011; 187: 2559-2568.
22. Noser JA, Mael AA, Sakuma R, Ohmine S, Marcato P, Lee PW et al. The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: implication for the defective interferon response in cancer cells. Mol Ther 2007; 15: 1531-1536.
23. Battcock SM, Collier TW, Zu D, Hirasawa K. Negative regulation of the alpha interferon-induced antiviral response by the Ras/Raf/MEK pathway. J Virol 2006; 80: 4422-4430.
24. Ayroldi E, Zollo O, Macchiarulo A, Di Marco B, Marchetti C, Riccardi C. Glucocorticoid-induced leucine zipper inhibits the Raf-extracellular signal-regulated kinase pathway by binding to Raf-1. Mol Cell Biol 2002; 22: 7929-7941.
25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.
26. Christian SL, Collier TW, Zu D, Licursi M, Hough CM, Hirasawa K. Activated Ras/MEK inhibits the antiviral response of alpha interferon by reducing STAT2 levels. J Virol 2009; 83: 6717-6726.
27. Ahmed M, Cramer SD, Lyles DS. Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses. Virology 2004; 330: 34-49.
28. Janelle V, Brassard F, Lapierre P, Lamarre A, Poliquin L. Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy. J Virol 2011; 85: 6513-6520.
29. Zhang KX, Matsui Y, Hadaschik BA, Lee C, Jia W, Bell JC et al. Down-regulation of type I interferon receptor sensitizes bladder cancer cells to vesicular stomatitis virus-induced cell death. Int J Cancer 2010; 127: 830-838.
30. Ezell SA, Polytarchou C, Hatziapostolou M, Guo A, Sanidas I, Bihani T et al. The protein kinase Akt1 regulates the interferon response through phosphorylation of the transcriptional repressor EMSY. Proc Natl Acad Sci USA 2012; 109: E613-E621.
31. Zhu J, Coyne CB, Sarkar SN. PKC alpha regulates Sendai virus-mediated interferon induction through HDAC6 and beta-catenin. EMBO J 2011; 30: 4838-4849.
32. Chun Y, Park B, Koh W, Lee S, Cheon Y, Kim R et al. New centromeric component CENP-W is an RNA-associated nuclear matrix protein that interacts with nucleophosmin/B23 protein. J Biol Chem 2011; 286: 42758-42769.
33. Okuwaki M. The structure and functions of NPM1/Nucleophsmin/B23, a multifunctional nucleolar acidic protein. J Biochem 2008; 143: 441-448.
34. Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer 2006; 6: 493-505.
35. Khodarev NN, Roizman B, Weichselbaum RR. Molecular pathways: interferon/stat1 pathway: role in the tumor resistance to genotoxic stress and aggressive growth. Clin Cancer Res 2012; 18: 3015-3021.